By all accounts its stock should be in the red today. CRISPR Therapeutics (NASDAQ: CRSP) only reported $864,000 in fourth-quarter revenue after Thursday's closing bell, leading to a loss of $1.37 per share versus analysts' estimates for a loss of only around $1.20 per share on sales of at least a few million dollars. Yet, as of 2:03 p.m. ET Friday, CRISPR shares are higher to the tune of 9.7%. What gives? Thank Vertex Pharmaceuticals (NASDAQ: VRTX), mostly. Where to invest $1,000 right now? Our analyst t ...

Core Insights - Casgevy, the gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $54 million in Q4 revenue and $116 million for the full year, with 64 patients receiving infusions in 2025, including 30 in Q4 [1] - The initiation of treatment for 147 patients globally in 2025 nearly tripled compared to 2024, indicating strong momentum heading into 2026 [1][2] - William Blair analysts express confidence that the increase in first cell collections will lead to significantly higher revenue in 2026 [2] - The company is advancing its in vivo liver editing programs, with CTX310 in Phase 1b trials for lipid disorders and CTX321 progressing through enabling studies, with updates expected in H2 2026 [2] - The siRNA-based candidate CTX611 is in Phase 2 trials for knee replacement surgery patients and may have broader applications in thromboembolic diseases [3] - CRISPR Therapeutics ended 2025 with $1.98 billion in cash and marketable securities, while R&D expenses rose to $83.5 million in Q4, and the net loss widened to $130.6 million from $37.3 million a year earlier [4] - CRISPR Therapeutics shares increased by 8.81% to $53.24 at the time of publication [4]

Key Takeaways CRISPR Therapeutics reported a wider Q4 loss of $1.37 per share and revenues of $0.9M, missing estimates.CRSP's partner Vertex logged $54M Q4 Casgevy sales, up from $16.9M, with momentum seen into 2026.CRISPR plans 2026 Casgevy label filings and advances CAR-T, in-vivo and RNA programs with updates due.CRISPR Therapeutics (CRSP) reported a fourth-quarter 2025 loss of $1.37 per share, wider than the Zacks Consensus Estimate of a loss of $1.15. The company had incurred a loss of 44 cents per sha ...

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.37 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $0.44 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -18.85%. A quarter ago, it was expected that this company would post a loss of $1.32 per share when it actually produced a loss of $1.17, delivering a surprise of +11.36%.Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland Not Applicable (State or other jurisd ...

Financial Performance - CASGEVY generated fourth quarter 2025 revenue of $54 million and full year 2025 revenue of $116 million, reflecting continued growth in treated patients[5] - Total revenue for Q4 2025 was $864,000, compared to $35,691,000 in Q4 2024, representing a significant decrease[25] - Collaboration revenue for the full year 2025 was $0, consistent with the previous year[25] - Grant revenue for Q4 2025 was $864,000, compared to $691,000 in Q4 2024, showing a 25% increase[25] - The company reported a comprehensive loss of $130,778,000 for Q4 2025, compared to a comprehensive loss of $46,036,000 in Q4 2024[25] - The basic net loss per common share for Q4 2025 was $1.37, compared to $0.44 for Q4 2024, indicating a worsening loss per share[25] Research and Development - R&D expenses were $83.5 million for the fourth quarter of 2025, compared to $71.7 million for the same period in 2024, primarily driven by increased licensing fees[14] - Research and development expenses for Q4 2025 were $83,526,000, up from $71,738,000 in Q4 2024, indicating a 16.5% increase[25] - CRISPR Therapeutics is advancing CTX310® in Phase 1b clinical trials, targeting severe hypertriglyceridemia and refractory hypercholesterolemia, with updates expected in the second half of 2026[5] - The company is progressing CTX213™, a beta cell replacement product candidate for Type 1 diabetes, towards clinical trials, with compelling preclinical efficacy demonstrated[8] - CTX611, a long-acting siRNA targeting Factor XI, is in an ongoing Phase 2 clinical trial, with updates expected in the second half of 2026, representing a multi-billion-dollar market opportunity[17] Patient Access and Treatment - 64 patients received infusions of CASGEVY during 2025, including 30 in the fourth quarter, with patient initiations and first cell collections increasing nearly three-fold compared to 2024[5] - As of year-end 2025, approximately 90% of patients in the U.S. have reimbursed access to CASGEVY, with expanded access in multiple countries[5] Financial Position - Cash, cash equivalents, and marketable securities were $1,975.8 million as of December 31, 2025, compared to $1,903.8 million as of December 31, 2024[14] - Cash and cash equivalents as of December 31, 2025, were $347,559,000, an increase from $298,257,000 as of December 31, 2024[27] - Total assets as of December 31, 2025, were $2,265,243,000, slightly up from $2,242,034,000 in the previous year[27] - Total shareholders' equity decreased to $1,921,813,000 as of December 31, 2025, from $1,932,080,000 in 2024[27] Collaboration and Expenses - Collaboration expense, net, was $53.7 million for the fourth quarter of 2025, compared to $10.4 million for the same period in 2024, reflecting the absence of a comparable deferral in 2025[14] - Net loss was $130.6 million for the fourth quarter of 2025, compared to a net loss of $37.3 million for the fourth quarter of 2024[14]

Core Insights - CRISPR Therapeutics reported financial results for Q4 and full year 2025, highlighting progress in its clinical and preclinical pipeline, including advancements in autoimmune diseases and oncology, as well as the global uptake of its therapy CASGEVY [1][2] Financial Performance - CASGEVY generated Q4 2025 revenue of $54 million and full year revenue of $116 million, with a significant increase in patient initiations and first cell collections, nearly tripling from 2024 to 2025 [5] - Cash, cash equivalents, and marketable securities totaled $1,975.8 million as of December 31, 2025, up from $1,903.8 million in 2024, primarily due to common share issuance and interest income [14] - R&D expenses for Q4 2025 were $83.5 million, an increase from $71.7 million in Q4 2024, driven by higher licensing fees [14] - The net loss for Q4 2025 was $130.6 million, compared to a net loss of $37.3 million in Q4 2024 [14] Pipeline Developments - The company is advancing its in vivo liver editing portfolio and has made progress with its siRNA collaboration with Sirius Therapeutics [2][4] - CTX310, targeting ANGPTL3, is in Phase 1b trials for severe hypertriglyceridemia and refractory hypercholesterolemia, with updates expected in H2 2026 [5] - CTX460, targeting SERPINA1 for alpha-1 antitrypsin deficiency, is expected to enter clinical trials in mid-2026 [5] - Zugo-cel is in ongoing Phase 1 trials for autoimmune diseases and hematologic malignancies, with updates anticipated in H2 2026 [10][17] Market Expansion - CASGEVY is approved in multiple regions, including the U.S., EU, and several Middle Eastern countries, with approximately 90% of U.S. patients having reimbursed access [5] - The company is expanding its regenerative medicine portfolio, including CTX213 for Type 1 diabetes, which has shown promising preclinical efficacy [9] Collaborations - CRISPR Therapeutics has a strategic collaboration with Vertex Pharmaceuticals for CASGEVY, with Vertex leading global development and commercialization [13] - The collaboration with Sirius Therapeutics focuses on developing siRNA therapies, with CTX611 being a key program targeting FXI for thromboembolic disorders [19]

Core Viewpoint - CRISPR Therapeutics is identified as a stock that has the potential to double by 2030, with analysts maintaining positive ratings despite some adjustments in price targets [1][2]. Group 1: Analyst Ratings and Price Targets - Citizens maintained an Outperform rating on CRISPR Therapeutics while reducing the price target from $86 to $80, citing an undervalued pipeline and potential late-stage development for up to seven opportunities in 2027 [1]. - Bank of America analyst Alec Stranahan reduced the price target for CRISPR Therapeutics from $93 to $90 while maintaining a Buy rating, reflecting adjustments across its US Biopharmaceuticals coverage [2]. Group 2: Market Context and Trends - Various factors are aligning positively for the biotech sector, including rewards for positive data, large-cap biopharma investing in M&A and licensing, an increasing backlog of private companies, better access to capital, and minimal effects from drug price regulation [4]. - The firm suggests that while biotech has returned, the primary uncertainty lies in the longevity of this trend [4]. Group 3: Company Overview - CRISPR Therapeutics is a gene editing company that develops gene-based medicines for serious human diseases using its CRISPR/Cas9 platform [5].

分组1: Market Overview - The pre-Davos market exhibited overwhelming bullish sentiment, while the post-Davos environment is characterized by renewed volatility, the Sell-America trade, a rallying gold price, and a consistently weak dollar [1] - A critical shift in global discourse from de-globalization to a new world order necessitates immediate re-imagining of supply chains, partnerships, and advancements in domestic AI and automated manufacturing in the US [1] 分组2: Investment Themes - The anticipated volatility should be viewed as a sign of an emergent market rather than a negative one, with a shift from the MAG7 to 'magnificent thematics' including new world order, AI automation, innovation, and longevity [2] - Investors are encouraged to focus on the other 473 companies in the S&P 500 rather than just mega-caps, as every company is now effectively a tech company [2] 分组3: Stock Recommendations - CRISPR Therapeutics (NASDAQ:CRSP) is highlighted as a stock expected to double by 2030, with a maintained Outperform rating and a reduced price target from $86 to $80, indicating an undervalued pipeline [7][8] - Summit Therapeutics Inc. (NASDAQ:SMMT) is also expected to double by 2030, with the FDA accepting its BLA for ivonescimab, targeting a significant unmet need in non-small cell lung cancer [12][14]

Core Insights - CRISPR Therapeutics (CRSP) is expected to exceed expectations in its fourth-quarter and full-year 2025 results, with earnings having beaten estimates by 11.36% in the last reported quarter [1] - The Zacks Consensus Estimate for quarterly sales is $4.00 million, while the earnings estimate is a loss of $1.15 per share [1] Financial Performance - CRISPR Therapeutics' revenue includes grants and collaboration income from its partnership with Vertex Pharmaceuticals (VRTX) [2] - The company has shown a decent performance over the past four quarters, beating earnings estimates in three of those quarters, with an average surprise of 15.23% [8] Product Development - The one-shot gene therapy, Casgevy, developed in partnership with VRTX, was approved for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in late 2023/early 2024, marking it as the only marketed product in CRISPR's portfolio [3] - Casgevy sales have been increasing, which is likely to improve collaboration expenses for the upcoming quarter [4] Future Prospects - Investors are keen on updates regarding global regulatory submissions planned for the first half of 2026, aiming for label expansion of Casgevy for younger patients [5] - CRISPR Therapeutics is developing novel CAR-T cell therapies, including zugo-cel, which is being evaluated in early-stage studies for various conditions [6] - The company is also advancing its in-vivo pipeline with candidates CTX310 and CTX320, and plans to introduce two more programs, CTX340 and CTX450, into clinical development by the end of the year [7] Earnings Prediction - The model predicts an earnings beat for CRISPR Therapeutics, supported by a positive Earnings ESP of +15.85% and a Zacks Rank of 3 [11][12] - The Most Accurate Estimate stands at a loss of $0.97 per share, compared to the Zacks Consensus Estimate of a loss of $1.15 [12]